Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.55 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.50 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.44 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.44 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30184245 | 1.00 | HTR6 (0.55) | HTR6CA1CA2TSHRCA12 | |
| SCHEMBL19110981 | 0.97 | HTR6 (0.58) | HTR6CA1CA2TSHRCA12 | |
| SCHEMBL323729 | 0.97 | HTR6 (0.58) | HTR6CA1CA2TSHRCA12 | |
| SCHEMBL7901727 | 0.89 | TDP1 (0.59) | HTR6CA1CA2TSHRCA12 | |
| Bicarbonate SCHEMBL29219000 | 0.89 | TSHR (0.52) | HTR6CA1CA2TSHRCA12 | |
| Phosphoric Acid SCHEMBL28712122 | 0.85 | ALDH1A1 (0.48) | HTR6CA1CA2TSHRCA12 | |
| Ethylamine SCHEMBL1436591 | 0.83 | PSIP1 (0.54) | HTR6CA1CA2TSHRCA12 | |
| SCHEMBL29128963 | 0.81 | CA12 (0.60) | CA1CA2TSHRCA12ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL30560569 | 0.81 | CES1 (0.45) | HTR6CA1CA2TSHRCA12 | |
| SCHEMBL11574176 | 0.81 | TSHR (0.56) | HTR6CA1CA2TSHRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099412-A1 | METHOD OF INHIBITING DEGRADING PROTEASE ACTIVITY IN AGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-03-27 | — | — | US | claimed |
| EP-4466008-A2 | METHOD OF INHIBITING DEGRADING PROTEASE ACTIVITY IN AGING | The Regents of the University of California (US) | 2024-11-27 | — | — | EP | claimed |
| WO-2024155293-A1 | METHOD OF INHIBITING DEGRADING PROTEASE ACTIVITY IN THE SKIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-25 | — | — | WO | claimed |
| WO-2024124212-A1 | DEVICES AND METHODS FOR DETECTION OF DISEASE BIOMARKERS AND THERAPEUTIC EFFECTIVENESS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-13 | — | — | WO | claimed |
| CN-115074336-B | Protein with phospholipidosis enzyme activity and purification method thereof | 电子科技大学 | 2024-03-22 | — | — | CN | claimed |
| WO-2023141125-A2 | METHOD OF INHIBITING DEGRADING PROTEASE ACTIVITY IN AGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-27 | — | — | WO | claimed |
| CN-115074336-A | Protein with phospholipid flippase activity and purification method thereof | 电子科技大学 | 2022-09-20 | — | — | CN | claimed |
| EP-3909509-A1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | Dyax Corp. (US) | 2021-11-17 | — | — | EP | claimed |
| EP-3193906-A1 | USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin (IE) | 2017-07-26 | — | — | EP | claimed |
| WO-2016042131-A1 | USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-03-24 | — | — | WO | claimed |
| EP-1750743-A4 | ORAL FORMULATIONS COMPRISING BONE MORPHOGENETIC PROTEINS FOR TREATING METABOLIC BONE DISEASES | GLAXOSMITHKLINE ZAGREB (HR) | 2009-07-08 | — | — | EP | claimed |
| EP-1750743-A2 | ORAL FORMULATIONS COMPRISING BONE MORPHOGENETIC PROTEINS FOR TREATING METABOLIC BONE DISEASES | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-02-14 | — | — | EP | claimed |
| WO-2005110465-A2 | ORAL FORMULATIONS COMPRISING BONE MORPHOGENETIC PROTEINS FOR TREATING METABOLIC BONE DISEASES | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2005-11-24 | — | — | WO | claimed |
| EP-4680243-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4577634-A1 | METHODS AND SYSTEMS FOR PROPAGATING MICROORGANISMS FOR MITIGATING MYCOTOXIN CONTAMINATION, AND RELATED SYSTEMS AND METHODS | POET Research, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4381094-B1 | ARGONAUTE-BASED NUCLEIC ACID DETECTION SYSTEM | UNIV WAGENINGEN (NL) | 2025-07-02 | — | — | EP | disclosed |
| CN-1759176-A | Diagnosis and treatment of multiple sulfatase deficiency and other disorders using formyl-glycine generating enzyme (FGE) | TRANSKARYOTIC THERAPIES INC (US) | 2006-04-12 | — | — | CN | disclosed |
| EP-1061963-A1 | PROTEASE INHIBITORS IN ABSORBENT ARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045974-A1 | PROTEASE INHIBITORS IN ABSORBENT ARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1996037474-A1 | SULFONYLQUINOLINES AS NEUROPEPTIDE Y1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |